About the Organ Transplantation Center

We are currently enrolling for the following studies:

Prophesys (MV21542)

Sponsor: Roche
Prospective, observational study on predictors of early on-treatment response and sustained virological response in a cohort of treatment naïve HCV-infected patients treated with pegylated interferons

One Group: Pegasys® or PegIntron® plus Ribavirin.

HepaGam (HB-009)

Sponsor: Cangene
Evaluation of HepaGam B in combination with antiviral treatment in Hepatitis B liver transplant patients

One Group: HepaGam B™ +Antiviral Treatment.